This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: I30 (acute pericarditis) | Special Copayment Reduction: V192 (special copayment reduction for heart disease: 5% copayment for up to 30 days from the registration date) |
| B. Synonyms | Acute pericarditis, idiopathic pericarditis, viral pericarditis, acute pericarditis, idiopathic pericarditis |
| C. Adult onset | Occurs mainly in young and middle-aged adults in their 20s–50s and is about 3 times more common in men than in women. Idiopathic (presumed viral) cases account for 70–80%, and with chest pain as the main symptom it is one of the leading causes of emergency admission. |
| 1. History | The evolution of the understanding and treatment of pericarditis, from ancient Egyptian descriptions to the 2025 ESC guidelines |
| 2. Causes | Idiopathic (presumed viral) 70–80%; infectious (including tuberculosis), autoimmune, neoplastic, uremic, post–myocardial infarction, etc. |
| 3. Genetics | Autoinflammatory predisposition, genetic variants in the IL-1 signaling pathway and HLA genotypes influence susceptibility to recurrent pericarditis |
| 4. General epidemiology | About 5% of admissions for non-traumatic chest pain; annual prevalence about 27.7/100,000 (Italy); recurrence rate about 20–30% |
| 5. Pathophysiology | Direct viral invasion and immune-mediated pericardial inflammation; the inflammasome–IL-1β axis is the key mechanism of recurrent pericarditis |
| 6. Symptoms | Sharp chest pain relieved by leaning forward; fever, palpitations; pleuritic pain worse on inspiration and when lying down |
| 7. Signs | Pericardial friction rub, fever, tachycardia, diminished heart sounds with pericardial effusion |
| 8. Screening | 12-lead ECG (diffuse ST elevation, PR depression), CRP, troponin and chest X-ray as basic screening |
| 9. Diagnosis | 2 or more of 4 diagnostic criteria; echocardiography and CMR are key for evaluating pericardial effusion and accompanying myocarditis |
| 10. Treatment | Combination of aspirin/NSAIDs + colchicine is first-line treatment; corticosteroids used second-line when these are contraindicated or ineffective |
| 11. Prognosis | Good prognosis for idiopathic pericarditis; recurrence rate 20–30%; progression to constrictive pericarditis is rare (<1%) |
| 12. Prevention | Prevent recurrence with 3 months of maintenance colchicine; avoid strenuous physical activity until resolution; early treatment of high-risk factors |
| 13. References | Imazio M, et al. A randomized trial of colchicine for acute pericarditis (COPE trial) … and 9 other papers |
Historical records of pericarditis go back to antiquity. Ancient Egyptian papyri and the writings of Hippocrates contain anatomical observations of the pericardium and surrounding structures, and in the 4th century BC Hippocrates described a condition in which water collects around the heart. However, acute pericarditis was recognized as a distinct clinical syndrome only in the 19th century. In 1818 Jean-Nicolas Corvisart systematically described the association between pathological changes of the pericardium and clinical symptoms, and René Laennec first described the pericardial friction rub using the stethoscope (invented in 1816).
In the late 19th and early 20th centuries, tuberculous pericarditis was recognized as the most common cause, but with advances in antituberculosis treatment its proportion fell markedly. When corticosteroids were introduced into clinical practice in the 1950s, they began to be used to treat acute pericarditis, but their use was later restricted after concerns arose about an increased risk of recurrence and adverse effects.
Colchicine had long been used to treat gout, but in 2005 Imazio et al. published the COPE study, showing that adding colchicine to aspirin in acute pericarditis reduced recurrence, which changed the treatment paradigm for pericarditis. The ICAP (2013), CORP (2011) and CORP-2 (2014) studies subsequently established colchicine's efficacy in preventing recurrence. The 2015 ESC guidelines on pericardial diseases adopted the strategy of combining colchicine with aspirin/NSAIDs in acute and recurrent pericarditis as a Class I recommendation.
As the importance of autoinflammatory mechanisms in the pathophysiology of recurrent pericarditis was recognized, the IL-1 receptor antagonist anakinra and the IL-1β monoclonal antibody rilonacept were studied as new treatment options for refractory recurrent pericarditis. In 2021 the RHAPSODY study showed that rilonacept reduced recurrences of pericarditis in recurrent pericarditis by 87%, leading to FDA approval, an important milestone that clinically confirmed the importance of autoinflammatory mechanisms. The 2025 ESC guidelines presented a new perspective that views pericarditis and myocarditis together as a spectrum of myopericardial disease.
The causes of acute pericarditis vary greatly by geographic location and patient population. Idiopathic pericarditis accounts for 70–80% of all cases in Western countries; it is presumed to be viral pericarditis in practice, but includes cases where a virus is difficult to identify. Known major causative viruses include coxsackievirus B1–B5, echovirus, adenovirus, cytomegalovirus (CMV), Epstein-Barr virus (EBV), influenza virus, parvovirus B19 and HIV. Because viral tests have low sensitivity and unclear cost-effectiveness, extensive viral identification testing is generally not recommended.
Tuberculous pericarditis is still the most common cause (over 70%) in developing countries, especially in southern Africa, and the risk rises markedly in people with HIV infection. Purulent pericarditis arises from direct bacterial infection (Staphylococcus, Streptococcus pneumoniae, gram-negative bacteria) and occurs with immunocompromised states, thoracic surgical procedures and as a complication of endocarditis. Autoimmune pericarditis occurs in systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), systemic sclerosis, Sjögren syndrome and sarcoidosis. Neoplastic pericarditis arises from metastasis or direct invasion of lung cancer (most common), breast cancer and lymphoma. Uremic pericarditis occurs in patients with end-stage kidney failure from pericardial irritation by uremic toxins and improves with dialysis. Radiation-induced pericarditis also has a chronic form that develops years after mediastinal radiation therapy.
The role of genetic factors in acute pericarditis is drawing attention particularly in recurrent pericarditis. In some patients with recurrent pericarditis, a pattern resembling autoinflammatory disease is observed, suggesting the involvement of genetic abnormalities in innate immune activation pathways. NLRP3 inflammasome activation and IL-1β oversecretion have been identified as the key mechanisms of recurrent pericarditis, and gain-of-function variants in the NLRP3 gene are associated with autoinflammatory diseases such as gout and periodic fever syndromes.
Variants in the MEFV gene, which cause familial Mediterranean fever (FMF), have been reported to be associated with recurrent pericarditis. Pericarditis with pericardial effusion can occur in FMF patients, related to overactivation of the pyrin inflammasome due to MEFV variants. There are reports that the risk of recurrent pericarditis may be increased even in heterozygous MEFV variant carriers. An association between recurrent pericarditis and variants in the TNFRSF1A gene, which cause TNF receptor–associated periodic syndrome (TRAPS), has also been reported in part.
In autoimmune-related pericarditis, HLA genotypes influence susceptibility. HLA-DR2 and HLA-DR3 are known susceptibility alleles in SLE-related pericarditis, and an influence of HLA-DR4 has been reported in rheumatoid arthritis–related pericarditis. No genetic marker specific to acute pericarditis itself has yet been established, but genes in the autoinflammatory pathway (NLRP3, MEFV, TNFRSF1A) can be used to assess the genetic background of recurrent refractory pericarditis.
Acute pericarditis is identified as the cause in about 5% of patients admitted through the emergency department with non-traumatic chest pain. An Italian study reported an annual incidence of about 27.7 per 100,000. It can occur at any age but is most common in men aged 15–35, with a male-to-female ratio of about 3:1, markedly more common in men. Seasonally, it occurs more often in spring and autumn, consistent with the seasonal pattern of viral infections.
Recurrent pericarditis occurs in about 20–30% after the first episode. Predictors of recurrence include no colchicine use in the first episode, high-dose corticosteroid use, a high CRP level at onset and specific causes (autoimmune, tuberculous, neoplastic). As recurrences accumulate, response to treatment tends to become more difficult. Progression to constrictive pericarditis is rare, occurring in 0.5–1% of all cases, and is more common mainly in tuberculous, purulent, neoplastic and autoimmune pericarditis. Cardiac tamponade occurs in about 1.2–4.5% of all acute pericarditis.
Epidemiological data on acute pericarditis in Korea are limited, but the proportion of tuberculous pericarditis tends to be relatively higher than in Western countries. In Korea, where tuberculosis prevalence is still not negligible, the possibility of tuberculous pericarditis should always be considered, especially in immigrants, homeless people, people with HIV infection and immunocompromised patients. Pericarditis after COVID-19 infection and COVID-19 mRNA vaccination has recently been reported, and a slight increase in the incidence of pericarditis after mRNA vaccination has been confirmed, particularly in males aged 16–24.
The pathogenesis of acute pericarditis differs by cause, but the common core is an inflammatory response of the pericardium. In viral pericarditis, the virus reaches the pericardium hematogenously or spreads directly from adjacent tissue. In the acute phase, direct viral cell destruction (direct cytotoxic effect) and the innate immune response to it (activation of viral recognition receptors, IFN-α/β production, NK cell activation) trigger the initial inflammation. The adaptive immune response (T lymphocytes, B lymphocytes) then takes charge of clearing the virus.
The reason pericardial inflammation persists in some patients even after viral clearance is explained by immune-mediated mechanisms. Molecular mimicry between viral antigens and self-antigens leads to the generation of autoreactive T cells and antibodies that attack pericardial cells. This mechanism resembles Dressler syndrome and is more prominent in recurrent pericarditis.
The autoinflammation pathway has recently drawn attention as the key mechanism of recurrent pericarditis. The NLRP3 inflammasome is activated in pericardial mesothelial cells and macrophages, leading to oversecretion of IL-1β and IL-18. IL-1β is a potent mediator of pericardial inflammation; it amplifies the production of other inflammatory cytokines (IL-6, TNF-α) and promotes neutrophil and monocyte infiltration. When this autoinflammatory loop is repeatedly activated even without an external stimulus, it results in recurrent pericarditis. Elucidation of this mechanism explains the therapeutic effect of IL-1 blockers (anakinra, rilonacept). In tuberculous pericarditis, Mycobacterium tuberculosis invades the pericardium directly or spreads from adjacent lymph nodes, causing granulomatous inflammation, and even after treatment can progress to constrictive pericarditis through fibrosis.
The most characteristic symptom of acute pericarditis is chest pain, present in about 85–90% of patients. The pain is sharp and stabbing, beginning behind the sternum or in the left chest and possibly radiating to the left shoulder and trapezius region. The most characteristic feature of pericarditis chest pain is change with posture: it is relieved by leaning forward or sitting up and worsens when lying down (especially supine). A pleuritic pattern that worsens on inspiration or swallowing is also characteristic.
Fever (38℃ or higher) appears in about 60–70% and may be accompanied by general malaise, myalgia and anorexia. As pericardial effusion increases, dyspnea and orthopnea may appear. With a large pericardial effusion, cardiac tamponade can develop, with rapid onset of dyspnea, hypotension, altered consciousness, cold sweats and pallor. With accompanying myocarditis (myopericarditis), myalgia, severe generalized weakness and palpitations due to arrhythmia are added. Troponin elevation is an indicator of myocardial involvement.
In recurrent pericarditis, the same or similar chest pain recurs repeatedly after weeks to months. Symptoms at recurrence are sometimes somewhat milder than in the first episode, but they impose a considerable psychological burden on patients and reduce their quality of life.
The most specific sign of acute pericarditis is the pericardial friction rub, heard in about 40–60%. It is a scratchy sound produced when the two inflamed layers of the pericardium rub against each other and consists of three components (presystolic, systolic and early diastolic), though often only one or two components are heard. It is best heard at the lower left sternal border, most clearly with the patient sitting and leaning forward at end-expiration. The rub may fluctuate, disappearing for short periods and then reappearing.
Fever (38–39℃) and tachycardia (heart rate >100/min) appear as signs of the systemic inflammatory response. As pericardial effusion increases, the rub may actually disappear and heart sounds diminish (muffled heart sounds), and chest percussion may reveal dullness corresponding to an enlarged cardiac silhouette. With a large pericardial effusion, loss or displacement of the apical impulse (PMI) is observed. As cardiac tamponade develops, paradoxical pulse, jugular venous distension and diminished heart sounds (Beck's triad) appear.
In patients with suspected acute pericarditis, an immediate 12-lead ECG is the most important initial screening test. The ECG changes characteristic of pericarditis progress through 4 stages. Stage 1: concave (saddle-shaped) ST-segment elevation and PR-segment depression in all leads (PR elevation and ST depression in aVR); stage 2: normalization of the ST segment; stage 3: T-wave inversion; stage 4: normalization of the ECG. These changes must be distinguished from the ST elevation of regional acute myocardial infarction. PR elevation in lead aVR is the most specific finding for pericarditis.
Serum C-reactive protein (CRP) is the most useful biomarker of acute-phase inflammation and is used to monitor treatment response and decide when to taper colchicine. A CRP-guided tapering strategy, reducing medication after CRP has normalized, is recommended. Complete blood count (CBC) and erythrocyte sedimentation rate (ESR) are also used to assess inflammation. Troponin I/T assesses myocardial involvement (myopericarditis), and if elevated, further testing (echocardiography, CMR) is needed. Renal function (BUN, creatinine) helps differentiate uremic pericarditis, and TSH helps differentiate pericardial effusion related to hypothyroidism.
The diagnosis of acute pericarditis is defined as meeting 2 or more of the following 4 criteria: (1) pericardial chest pain, (2) pericardial friction rub, (3) ECG findings (new widespread ST elevation or PR depression), (4) new or worsening pericardial effusion. CRP elevation and imaging evidence of pericardial inflammation (CMR) are supporting findings.
Transthoracic echocardiography (TTE) is essential to assess the presence, extent and distribution of pericardial effusion and to rule out cardiac tamponade. The absence of pericardial effusion does not exclude a diagnosis of pericarditis. Cardiac magnetic resonance imaging (CMR) precisely evaluates pericardial inflammation (late gadolinium enhancement, T2 elevation), pericardial effusion and accompanying myocarditis, and is especially useful when troponin is elevated or differentiation from acute myocardial infarction is needed. Pericardial LGE seen on CMR correlates with the degree of pericardial fibrosis and the risk of recurrence.
Cause-specific tests include ADA (adenosine deaminase), the PPD tuberculin skin test, IGRA and AFB culture of pericardial fluid when tuberculosis is suspected. To differentiate autoimmune disease, ANA, anti-dsDNA, RF, ANCA, complement levels and others are measured. Cytology, culture and biochemical analysis of pericardial fluid obtained by pericardiocentesis are important for differentiating purulent, tuberculous and neoplastic pericarditis. Tissue biopsy via pericardioscopy is performed only in limited cases where a specific cause is strongly suspected but not confirmed by other tests.
The standard treatment for idiopathic or viral acute pericarditis is combination therapy with aspirin or NSAIDs and colchicine. Aspirin (750–1000mg every 8 hours, for 1–2 weeks) is preferred, and ibuprofen (600mg every 8 hours, for 1–2 weeks) is also effective. At the same time, colchicine (0.5mg twice daily; 0.5mg once daily for body weight under 70kg) is given for 3 months to prevent recurrence. Physical activity is restricted until symptoms and CRP normalize, and in professional athletes normalization on echocardiography is confirmed before return.
Corticosteroids (prednisolone 0.2–0.5mg/kg/day) are used second-line when aspirin/NSAIDs are contraindicated (pregnancy, NSAID intolerance, certain accompanying autoimmune diseases) or when the condition is refractory after 2–4 weeks of treatment. Early after infarction they are avoided where possible because of the risk of ventricular rupture. Steroids are used at the lowest possible dose and tapered slowly after CRP normalizes, with colchicine maintained during the taper.
IL-1 inhibitors are a new treatment option for refractory recurrent pericarditis. Anakinra (IL-1R antagonist) 100mg/day by subcutaneous injection is effective in steroid-dependent recurrent pericarditis. Rilonacept (IL-1α/IL-1β blockade) showed high efficacy in preventing recurrence in the RHAPSODY study and received FDA approval. Purulent pericarditis requires drainage (pericardiocentesis or surgical) and antibiotic therapy targeted to the pathogen. Tuberculous pericarditis is treated with standard four-drug antituberculosis therapy, and the role of adjunctive corticosteroid therapy to prevent effusive-constrictive pericarditis is under discussion (IMPI study).
The prognosis of idiopathic or viral acute pericarditis is generally good. With appropriate treatment, symptoms resolve within 2–3 weeks in most patients. Pericardial effusion also often disappears within a few weeks. Progression to constrictive pericarditis is very rare, occurring in fewer than 0.5–1% of all cases, and the risk is higher mainly in tuberculous, purulent, radiation-induced, autoimmune and post-traumatic pericarditis.
Recurrence is the most common complication, occurring in about 20–30%. Three months of colchicine reduces the risk of recurrence by about 50% (ICAP study). Patients with recurrent pericarditis have a slightly higher risk of progression to constrictive pericarditis than after a first episode, so long-term follow-up is needed. With accompanying myocarditis (myopericarditis), the course is generally benign and ventricular function mostly recovers. However, when there is marked troponin elevation and extensive myocardial LGE on CMR, there is a risk of arrhythmia and heart failure, so follow-up is needed.
Poor prognostic factors ("triage signs") include fever >38℃, subacute onset (gradual progression over weeks), large pericardial effusion (posterior effusion >20mm on echocardiography), no response to aspirin/NSAIDs, accompanying myocarditis (troponin elevation), immunocompromised state and ongoing anticoagulant therapy. Inpatient treatment is recommended when such high-risk factors are present.
The most important strategy to prevent recurrence of acute pericarditis is to maintain colchicine fully for 3 months in the first episode. Stopping colchicine early, even if symptoms improve, increases the risk of recurrence, so it is tapered slowly while confirming CRP normalization. NSAIDs and aspirin are also maintained for several weeks after symptom resolution, until CRP normalizes.
Patients are educated to avoid strenuous physical activity until acute pericarditis has fully resolved. Return to competitive sports is allowed only after resolution of symptoms, normalization of CRP, and normalization of the ECG and echocardiogram have all been confirmed. Activity restriction for 3 months is recommended in general patients, and for a longer period with accompanying myocarditis. This is to prevent mechanical injury to the inflamed pericardium and to prevent recurrence.
When tuberculosis is the cause, completing standard antituberculosis treatment is the key to prevention. When an autoimmune disease is the underlying cause, ongoing management of the underlying disease and immunosuppressive therapy contribute to preventing recurrence of pericarditis. In recurrent refractory pericarditis, long-term use of IL-1 inhibitors is effective in preventing recurrence and reducing steroid dependence. Appropriate vaccinations to prevent infection (influenza, pneumococcal) and hygiene also help prevent viral pericarditis.
Imazio M, Bobbio M, Cecchi E, et al. Colchicine in addition to conventional therapy for acute pericarditis: results of the COlchicine for acute PEricarditis (COPE) trial. Circulation. 2005;112(13):2012-2016. DOI: 10.1161/CIRCULATIONAHA.105.542738. PMID: 16186437.
Imazio M, Brucato A, Cemin R, et al. A randomized trial of colchicine for acute pericarditis (ICAP). New England Journal of Medicine. 2013;369(16):1522-1528. DOI: 10.1056/NEJMoa1208536. PMID: 23992557.
Adler Y, Charron P, Imazio M, et al. 2015 ESC Guidelines for the diagnosis and management of pericardial diseases. European Heart Journal. 2015;36(42):2921-2964. DOI: 10.1093/eurheartj/ehv318. PMID: 26320112.
Klein AL, Abbara S, Agler DA, et al. American Society of Echocardiography clinical recommendations for multimodality cardiovascular imaging of patients with pericardial disease. Journal of the American Society of Echocardiography. 2013;26(9):965-1012. DOI: 10.1016/j.echo.2013.06.023. PMID: 23998693.
Khandaker MH, Espinosa RE, Nishimura RA, et al. Pericardial disease: diagnosis and management. Mayo Clinic Proceedings. 2010;85(6):572-593. DOI: 10.4065/mcp.2010.0046. PMID: 20511488.
Brucato A, Imazio M, Gattorno M, et al. Effect of anakinra on recurrent pericarditis among patients with colchicine resistance and corticosteroid dependence. JAMA. 2016;316(18):1906-1912. DOI: 10.1001/jama.2016.15826. PMID: 27825009.
Klein AL, Lin D, Cremer PC, et al. Rilonacept for recurrent pericarditis among patients with an inadequate response to conventional medical therapy: a randomised trial. Lancet. 2021;397(10293):2429-2438. DOI: 10.1016/S0140-6736(21)00714-5. PMID: 34062131.
Mayosi BM, Ntsekhe M, Bosch J, et al. Prednisolone and Mycobacterium indicus pranii in tuberculous pericarditis. New England Journal of Medicine. 2014;371(12):1121-1130. DOI: 10.1056/NEJMoa1407380. PMID: 25229917.
Imazio M, Gaita F, LeWinter M. Evaluation and treatment of pericarditis: a systematic review. JAMA. 2015;314(14):1498-1506. DOI: 10.1001/jama.2015.12763. PMID: 26461998.
Imazio M, Belli R, Brucato A, et al. Efficacy and safety of colchicine for treatment of multiple recurrences of pericarditis (CORP-2): a multicentre, double-blind, placebo-controlled, randomised trial. Lancet. 2014;383(9936):2232-2237. DOI: 10.1016/S0140-6736(13)62709-9. PMID: 24694983.